Gil Blum, an analyst from Needham, maintained the Buy rating on TScan Therapeutics (TCRX – Research Report). The associated price target remains the same with $9.00.
Gil Blum has given his Buy rating due to a combination of factors influencing TScan Therapeutics’ future prospects. The company has reiterated its clinical development timelines, indicating a clear path forward for its pipeline. Notably, TScan is preparing to release initial multiplex data across various tumor types by the end of 2025, which will focus on early safety and efficacy, with more comprehensive updates expected in 2026.
Additionally, TScan is on track to begin a pivotal study for TSC-101 in the second half of 2025, following a meeting with the FDA. The anticipated topline results from this study are expected in the latter half of 2027. Financially, TScan is in a strong position, ending the first quarter of 2025 with $252 million in cash, which is projected to support its operations into the first quarter of 2027. These factors collectively contribute to the positive outlook and the Buy rating assigned to TScan Therapeutics.
Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Autolus Therapeutics, and Immunocore Holdings. According to TipRanks, Blum has an average return of -11.5% and a 32.34% success rate on recommended stocks.